DDInter298 DDInter1492
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Ponatinib
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Carboplatin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Ponatinib
Carboplatin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Sodium bicarbonate
Sodium bicarbonate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is regulated by {v} (Gene) EP300
EP300 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ponatinib (Compound)
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Ponatinib (Compound)
Carboplatin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Ponatinib (Compound)
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Ponatinib (Compound)
Carboplatin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Sodium bicarbonate (Compound) and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Ponatinib (Compound)
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is regulated by EP300 (Gene) and EP300 (Gene) is upregulated by Ponatinib (Compound)